Loading organizations...
§ Private Profile · Lingan, Zhejiang, China
Biotechnology company developing precision oncology therapies for solid tumor patients, focused on its BioTroy Engine platform.
Founded in 2019, BioTroy Therapeutics is a biotechnology company that develops precision oncology therapies using its proprietary BioTroy Engine platform to analyze tumor multi-omics, functional biology, and antibody engineering. The organization utilizes this advanced technology to identify first-in-class biological targets for solid tumor treatments, producing multiple published discoveries that include novel ligands for LILRB4 and CD3ε. Its lead clinical asset, a monoclonal antibody designated as BT02, targets the novel immune checkpoint ITPRIPL1 and has successfully secured Investigational New Drug clearances from both the United States FDA and China's NMPA. This primary therapeutic candidate is scheduled to advance into Phase I and II clinical trials for solid tumors during the second quarter of 2025. To support its ongoing research and clinical development pipeline, the enterprise has raised over $21 million, or approximately 150 million RMB, in venture capital funding.
BioTroy Therapeutics has raised $14.5M across 1 funding round.
BioTroy Therapeutics has raised $14.5M in total across 1 funding round.
BioTroy Therapeutics has raised $14.5M across 1 funding round. Most recently, it raised $14.5M Pre-Series A in March 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 19, 2023 | $14.5M Seed Plus | Wind Capital | Hongke Baishi, Shanghai Biopharma Fund | Announced |
BioTroy Therapeutics has raised $14.5M in total across 1 funding round.
BioTroy Therapeutics's investors include Wind Capital, Hongke Baishi, Shanghai BioPharma Fund.